205187-83-3

Upstream product

• 205187-84-4 4-dimethylamino-3-methoxy-benzyl alcohol 
• 205187-82-2 4-Dimethylamino-3-methoxy-benzoic acid ethyl ester 
• 128495-46-5 4-fluoro-3-methoxybenzaldehyde 
• 124-40-3 dimethyl amine 
• 67-56-1 methanol 
• 100-10-7 4-dimethylamino-benzaldehyde 

Downstream Products

• 2428-37-7 1-<3-Methoxy-4-dimethylamino-benzyliden>-inden 
• 205187-86-6 (4-Dimethylamino-3-methoxy-phenyl)-trimethylsilanyloxy-acetonitrile 
• 930284-65-4 (E,E)-2,6-bis(3-methoxy-4-dimethylaminostyryl)benzene 
• 205187-87-7 (4-Dimethylamino-3-methoxy-phenyl)-hydroxy-acetic acid methyl ester 
• 205187-85-5 (4-Dimethylamino-3-methoxy-phenyl)-hydroxy-acetic acid 
• 930284-53-0 (E,E)-2,6-bis(3-methoxy-4-dimethylaminostyryl)pyridine 

Relevant academic research and scientific papers

Dicyanovinyl-substituted J147 analogue inhibits oligomerization and fibrillation of β-amyloid peptides and protects neuronal cells from β-amyloid-induced cytotoxicity

A series of novel J147 derivatives were synthesized, and their inhibitory activities against β-amyloid (Aβ) aggregation and toxicity were evaluated by using the oligomer-specific antibody assay, the thioflavin-T fluorescence assay, and a cell viability assay in the transformed SH-SY5Y cell culture. Among the synthesized J147 derivatives, 3j with a 2,2-dicyanovinyl substituent showed the most potent inhibitory activity against Aβ42 oligomerization (IC50 = 17.3 μM) and Aβ42 fibrillization (IC50 = 10.5 μM), and disassembled the preformed Aβ42 fibrils with an EC50 of 10.2 μM. Finally, we confirmed that 3j is also effective at preventing neurotoxicity induced by Aβ42-oligomers as well as Aβ42-fibrils.

Fluorescent pH-Responsive Probes Based on Water-Soluble Boron-Dipyrromethene (BODIPY) Derivatives, Featuring Long-Wavelength Emission

We describe here the synthesis of water-soluble red/NIR-emissive, boron-dipyrromethene (BODIPY) derivatives displaying optical (absorption and emission) responses in pH range of 4–8. Substitution close to the tertiary aniline or the phenol subunits select

A novel anti-Alzheimer agent inhibiting oligomerization and fibriliation of beta-amyloid protects neuronal cell from Aβ-induced cytotoxicity

The present invention relates to development of a novel treatment agent for Alzheimerandprime;s disease, having ability of protecting neural cells and inhibiting fibrosis and oligomerization of beta-amyloid. A compound of the present invention is capable of, while maintaining therapeutic effects on Alzheimerandprime;s disease, recovering ability of directly inhibiting oligomerized and fibrous amyloid beta, which is inherent activities of existing curcumin, thereby being useful as a novel inhibitor.COPYRIGHT KIPO 2017

Electrochemical methoxylation of some benzaldehyde derivatives at platinum electrode

The electrochemical methoxylation of 4-chlorobenzaldehyde, 4-hydroxybenzatdehyde, 4-anisylaldehyde and 4,4-N,N′- dimethylaminobenzaldehyde was carried out at platinum electrode. Constant potential electrolysis was carried out in undivided electrochemical cell. The reaction is an example of nuclear oxidation of aromatic compounds with substitution. The experimental parameters involved in the reaction are discussed here.

NOVEL CURCUMIN DERIVATIVE

The present invention provides a novel compound that is structurally similar to curcumin and has a suppressive effect on Aβ aggregation, a degradative effect on Aβ aggregates, an inhibitory effect on β-secretase, and a protective effect on neurons. The novel compound is a compound represented by the following general formula (Ia) or a salt thereof: wherein R1 represents a 4-hydroxy-3-methoxyphenyl group or the like, and R2 represents a 1H-indol-6-yl group or the like.

Antibody-catalyzed decarboxylative oxidation of vanillylmandelic acid

The most important industrial process for the synthesis of vanillin is performed in two steps involving an electrophilic aromatic substitution of glyoxylic acid on guaiacol followed by an oxidative decarboxylation of the intermediary α-hydroxy acids formed, thereby producing not only vanillin, but also byproducts which have to be eliminated. In the present study, we took advantage of the high specificity of catalytic antibodies to improve the synthesis of vanillin. Among 11 monoclonal antibodies elicited against the quaternary ammonium hapten H3, antibody H3-12 was found to catalyze the oxidative decarboxylation of vanillylmandelic acid (VMA), the precursor of vanillin, in the presence of sodium metaperiodate. The kinetic data of the antibody-catalyzed reaction are consistent with an ordered binding mechanism. At pH 9.0, H3-12 catalyzed the transformation of VMA into vanillin with a k(cat) of 2.70 min-1, a Michaelis-Menten constant K(a) for the binary complex of 260 μM, and a K(b) for the ternary complex of 2100 μM. The catalyzed reaction was fully inhibited by a hapten analogue with a K(i) of 10 μM. The fine specificity of anti-H3 monoclonal antibodies was determined using H3-related compounds with a competitive enzyme immunoassay. Controls demonstrating that catalytic activity is actually related to antibody binding, and mechanistic studies, are also presented.